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Abstract: Experimental studies have shown that two main estrogen metabolites   hydroxylated 
by CYP1A1 and CYP1B1 in the breast differentially affect breast cell proliferation and 
  carcinogenesis. Although 16α-hydroxyestrone (16αOHE1) exerts estrogenic activity through 
covalent estrogen receptor (ER) binding, 2-hydroxyestrone (2OHE1) presumably has antiestro-
genic capabilities. The ratio of 2OHE1 to 16αOHE1 represents the relative dominance of one 
pathway over the other and is believed to be modifiable by diet. It was hypothesized that women 
with or at high risk of breast cancer have a lower estrogen metabolite ratio (EMR) compared 
with women without breast cancer. We conducted a systematic review on the EMR as a predictor 
for breast cancer. A total of nine studies (six prospective and three retrospective) matched our 
inclusion criteria, comprising 682 premenopausal cases (1027 controls) and 1189 postmeno-
pausal cases (1888 controls). For the highest compared with the lowest quantile of urinary EMR, 
nonsignificant associations suggested at best a weak protective effect in premenopausal but not in 
postmenopausal breast cancer (range of odds ratios: 0.50–0.75 for premenopausal and 0.71–1.31 
for postmenopausal). Circulating serum/plasma EMR was not associated with breast cancer 
risk. Associations were inconclusive for receptor subtypes of breast cancer. Uncontrolled factors 
known to be involved in breast carcinogenesis, such as 4-hydroxyestrone (4OHE1) concentration, 
may have confounded results for EMR. Results of the prospective studies do not support the 
hypothesis that EMR can be used as a predictive marker for breast cancer risk. Future research 
should concentrate on profiles of estrogen metabolites, including 4OHE1, to gain a more com-
plete picture of the relative importance of single metabolites for breast cancer.
Keywords: estrogen metabolite ratio, 2-hydroxyestrone, 16α-hydroxyestrone, breast cancer, 
predictive marker, review
Introduction
Hypothesis (the extended hormonal risk factor hypothesis)
It is well known that endogenous estrogens have the potential of inducing and   promoting 
cell proliferation and inducing tumor growth in breast tissue.   Circulating estrogen   levels 
correlate with breast cancer risk in postmenopausal women.1,2 For   premenopausal 
women, the estrogen–breast cancer association is not as well established. Some   evidence 
for an association was found in one prospective study3 but was not statistically signifi-
cant in five other studies,4 probably due to the much higher intra- and interindividual 
variation through menstrual cycle and reproductive lifetime.5,6
Since the early 1980s, a growing number of studies examined whether not only 
native estrogens but also their hydroxylated estrogen metabolites have potential 
  carcinogenic properties in breast tissue. Experimental   studies in breast cancer cells International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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and animal models established the hypothesis of a differ-
ential estrogenic activity of the two main estrogen metabo-
lites, 2-hydroxyestrone (2OHE1) and 16α-hydroxyestrone 
(16αOHE1). Because 2OHE1 has a weak binding capacity 
to the ER and has been associated with normal cell differ-
entiation and apoptosis,7–9 it is assumed to have antiestro-
genic properties.10 In contrast, the other major metabolite, 
16αOHE1, can bind covalently to the ER and has been shown 
to induce abnormal cell proliferation.11,12
Both 2- and 16α-estrogen hydroxylating pathways are 
mutually exclusive and irreversible. Thus, the metabolite 
ratio of 2OHE1 to 16αOHE1 reflects the relative dominance 
of one pathway over the other. Since several relatively 
  small-scale observational studies and human breast tissue 
studies found lower ratio levels accompanied by higher 
16αOHE1 concentrations in breast cancer cases compared 
with women without breast cancer,13–18 it has been suggested 
that this ratio may be used as a marker for the assessment of 
breast cancer risk. Subsequent studies yielded   inconsistent 
results as to whether a lower ratio is associated with a 
higher risk for breast cancer, both in premenopausal and in 
  postmenopausal women.
A concurrent hypothesis postulates that the catecholestro-
gens 2OHE1/2OH-estradiol and especially the 4-hydroxylated 
estrogens 4-hydroxyestrone (4OHE1) and 4-hydroxyestradiol 
may play an important role in breast carcinogenesis because 
of their ability to induce DNA depurination independent 
of ER binding.19,20 Although experimental studies have 
  demonstrated the carcinogenic potential of 4OHE1,21,22 
little attention has been given to 4OHE1 in epidemiological 
  studies. Therefore, we focus here on the estrogen metabolite 
ratio (EMR) of 2OHE1 to 16αOHE1.
Metabolism of endogenous estrogens, 
genetic polymorphisms
In a first step, native 17β-estradiol (E2) and its oxidized 
form, estrone (E1), are metabolized to various hydroxylated 
estrogens by cytochrome P450-dependent pathways. The 
catecholestrogens 2OHE1/E2 and 4OHE1/E2 are character-
ized by two neighboring hydroxyl groups, which are rapidly 
methylated by the enzyme catechol-O-methyltransferase 
(COMT) to form 2-Meth-O-E1/E2 or 4-Meth-O-E1/E2. 
Further oxidation of unmethylated hydroxyestrogens may 
generate semiquinones and quinones, which on one hand 
can function as substrate for redox cycling processes, lead-
ing to reactive oxygen species (ROS), and on the other hand 
can bind to DNA to form stable or depurinating adducts 
with adenine or guanine. Subsequently, quinones and 
  hydroxylated estrogens, including 16αOHE1, are sulphatized 
or glucuronidated before excretion.23 The tissue-specific 
hydroxylases are encoded by CYP1A1, CYP1B1 (breast), 
and CYP1A2 (liver) for the 2-hydroxylation of E1 to form 
2OHE1/E2 and CYP1A1, CYP3A5 (breast),24 CYP3A4, 
and CYP3A725 for 16α-hydroxylation. A smaller fraction of 
estrogens is hydroxylated to 4OHE1/E2 by CYP1B1 (breast) 
and CYP1A2 (liver) enzymes.22 Tissue concentrations of 
the CYP enzymes vary considerably, and many of them 
are genetically polymorph, which implicates differences in 
  activity levels of the hydroxylases.26,27 Polymorphisms have 
also been described for COMT, leading to slower methylation 
of catecholestrogens.28,29
Menopausal status
To date, it is not well established whether the menopausal 
  transition is accompanied by a general shift of the EMR 
to favor 16αOHE1, as has been previously discussed.30 
Although levels of estrogen metabolites are several times 
higher in premenopausal compared with postmenopausal 
women, a   woman’s metabolite ratio seems to be relatively 
stable throughout her life.31 Most of the earlier studies on the 
EMR reported no significant mean differences between pre- 
and postmenopausal control groups without breast cancer.32 
Because the limited available data do not provide clear 
indication of an important influence of menopausal status 
on the EMR, both pre- and postmenopausal women were 
considered in this review.
The purpose of the present review was to evaluate 
the   evidence for an inverse relation between EMR and 
breast cancer risk and whether this ratio can potentially serve 
as a predictive marker.
Methods
Selection of studies
A PubMed/MEDLINE search on epidemiologic studies 
of estrogen metabolites and breast cancer was conducted 
up to February 2010. The search strategy consisted of 
a   combination of MeSH terms (“hydroxyestrones” and 
“breast neoplasms”) and key words in titles and abstracts 
(“estrogen metabolites”, “2-hydroxylation”, and “breast 
cancer”). References from resulting articles were screened 
for missed studies. If only abstracts of publications were 
available, they were excluded from the review.
Inclusion criteria
Studies were included in this review if risk estimates and 
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(2OHE1/16αOHE1) were reported for subjects not taking 
oral contraceptives, hormones, or tamoxifen and not pregnant 
at the time of blood donation or urine collection. Further 
requirements included frequency or individual matching of 
controls to cases by age and stratification by or adjustment for 
menopausal status to assess potentially differential evidence 
for pre- and postmenopausal women.
Measurement of the  
2OHe1/16αOHe1 eMR
All but one study,33 which employed an earlier version, used 
an improved enzyme immunoassay34 (ELISA; ESTRAMET, 
Immunacare Corporation, Bethlehem, PA, USA) developed 
by Klug et al35 for simultaneous urinary metabolites assess-
ment. The assay measures three of at least 15 metabolites 
and parent estrogens, ie, 2OHE1, 2-hydroxyestradiol 
(2OHE2), and 16αOHE1. Therefore, the EMR reflects the 
2OHE1 + 2OHE2/16αOHE1 ratio. The EMR is independent 
of urinary creatinine concentration.
Data extraction
To compare the median/mean EMR across studies, the third 
quintile’s midpoint of EMR in pre- and   postmenopausal 
controls has been derived as an approximate value for 
Muti et al36 and the numbers in each tertile in the study 
by Meilahn et al33 were deduced from given percentages. 
Risk estimates for quantiles and 95% CIs of the EMR were 
extracted from the tables of the publications and analyzed. To 
test for overall heterogeneity and heterogeneity by specimen 
type (urine, serum/plasma), risk estimates were weighted and 
pooled, and Cochran’s Q statistic37 was calculated.
Results
Overall, 21 studies were identified that dealt with any kind 
of estrogen metabolites and associated breast cancer risk, of 
which nine were included in this review (Table 1). One study 
included only premenopausal women38 and four studies only 
postmenopausal women,39–42 and the remaining four studies 
matched for menopausal status or analyzed data stratified by 
menopausal status.33,36,43,44
excluded studies
The main reasons for exclusion were nonavailability of risk 
estimates, including CIs of the association between EMR and 
breast cancer,13,14,18,45–51 and recruitment of control subjects 
from convenient samples that were not individually matched 
to cases by age.13,14,16–18,45,46,48,51 Almost all of these small 
case-control studies, comprising, in total, 401 cases and 
429 controls, found lower mean EMRs in cases compared 
with controls (Supplementary Table). Kabat et al17 reported 
for a small hospital-based study an extreme risk reduction for 
the third versus first tertile of urinary EMR in postmenopausal 
women (adjusted odds ratio [OR]: 0.03, 95% CI: 0.003–0.29), 
but not in the combined group of pre- and postmenopausal 
women (OR: 0.51, 95% CI: 0.17–1.56). Similarly, Ho et al16 
who used controls with biopsies for benign breast disease, 
found at a urinary EMR median cut-point of 0.9 a strong 
inverse association independent of menopausal status 
(OR: 0.16, 95% CI: 0.05–0.49).
Included studies
The nine studies included were published between 1998 
and 2009. Study characteristics are summarized in Table 1. 
In total, these studies comprised 682 premenopausal cases 
and 1027 premenopausal controls (five studies) and 1189 
  postmenopausal cases and 1888 postmenopausal con-
trols (seven studies). Six studies were nested case-control 
  studies within prospective cohorts,33,36,38,40–42 and three were 
  retrospective population-based case-control studies39,43,44 with 
determination of the metabolites after disease onset.   Studies 
were conducted in China,44 Italy,36 the UK,33 Denmark,41 
and the US.38–40,42,43 The baseline age distribution varied 
naturally across studies according to menopausal status, 
with the   minimum age ranging from 25 years44 to 65 years.40 
All studies were matched for age, and   prospective but not 
  retrospective studies in premenopausal women were addition-
ally matched for phase of menstrual cycle at time of specimen 
sampling (follicular or luteal33,38 and only luteal).36 Median 
follow-up time between specimen sampling and diagnosis of 
breast cancer (approximately equal to time between sampling 
and laboratory analysis) ranged from 2.4 years in the Dan-
ish cohort41 to 12–18 years in one of the US cohorts.38 The 
retrospective studies collected urine prior to any therapy for 
several months,44 a median of 3 months,43 or several years39 
after diagnosis.
Six studies investigated urinary excretion of estrogen 
metabolites, and three of the more recent studies examined 
serum/plasma concentrations.38,40,42 Among controls, mean 
urinary EMR values were consistently above 1, whereas means 
of circulating EMR were all below 1. In Western countries, 
urinary mean EMR varied between 1.9 and 2.57 in controls, 
whereas in the Shanghai study by Fowke et al44 the mean EMR 
was around 50% lower. A significant difference between pre- 
and postmenopausal controls in mean urinary EMR has been 
found only in the UK cohort.33 Studies of serum/plasma EMR 
examined either pre- or postmenopausal women.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Table 1 Characteristics of included studies on eMR and breast cancer risk estimates
Authors Country Design Medium Age (range and/or  
mean (SD))
Cases/controls  
(total)
Cases/controls 
(in models)
EMR  
(2OHE1/16αOHE1)
Adjusted OR  
(95% CI)
Ptrend Adjustment Notes (median, mean  
or gmean in controls)
Premenopausal
Meilahn et al33 UK Prospective nested  
case-control
Spot urine .34 (40.5 (4.2)) 60/184 21/62
22/61
17/61
,1.72
1.72–,2.44
$2.44
1
0.99 (0.48–2.08)
0.75 (0.35–1.62)
NA Age + menstrual phase  
matching; parity, others  
not exactly specified
Median follow-up 9.5 years,  
median eMR 2.1
Muti et al36 Italy Prospective nested  
case-control
12-h urine 35–57 67/264 19/54
14/51
11/52
12/54
11/53
,1.8
1.8–2.3
2.3–2.72
2.72–3.29
$3.29
1
0.76 (0.34–1.69)
0.60 (0.25–1.44)
0.62 (0.27–1.45)
0.55 (0.23–1.32)
NA Age + menstrual phase  
matching, BMI,  
waist-to-hip, reproductive  
variables
Mean follow-up 5.5 years,  
median eMR 2.5
Kabat et al43 USA Population-based  
case-control
Spot urine ,50–.60 105 (70 is)/129 44/46
35/42
26/41
#1.4
1.5–2.2
$2.3
1
0.63 (0.33–1.23)
0.50 (0.25–1.01)
0.05 Age matching, parity/first  
birth age, family history,  
BMI, education, medication  
(48 h prior urine collection)
In situ Ca separately; smoking,  
alcohol, diet prior tested; mean  
eMR (SD) 1.9 (1.0)
Arslan et al38 USA Prospective, nested  
case-control 
Serum 35–65
44.3 (4.8)
377/377 Not given for 
quartiles
,0.45
0.453–0.635
0.636–0.936
.0.936
1
0.83 (0.53–1.31)
1.04 (0.65–1.65)
1.13 (0.68–1.87)
0.51 Age + menstrual phase matching; family 
history, ever smoking, BMI, menarche  
age, parity/first birth age
12–18 years of follow-up, mean  
eMR (SD) 0.76 (0.49)
Mixed menopausal
Fowke et al44  
(presurgical)a
China Population-based  
case-control
Spot urine 25–65 78/78 presurgical 30/20
25/27
23/31
#0.69
0.70–1.22
$1.22
1
0.5 (0.2–1.3)
0.5 (0.2–1.3)
0.17 Matched for age and menopause; family 
history, physical activity, BMI, age at  
menarche, parity/first birth age,  
fibroadenoma history
Separate models for presurgical and   
postsurgical; presurgical included  
19/19 postmenopausal; median  
eMR 1.0
Fowke et al44  
(postsurgical)a
China Population-based  
case-control
Spot urine 25–65 32/32 postsurgical 5/14
10/11
17/7
#0.69
0.70–1.22
$1.22
1
3.1 (0.4–23.6)
8.1 (1.2–54.6)
0.02 Matched for age and menopause; family 
history, physical activity, BMI, age at  
menarche, parity/first birth age,  
fibroadenoma history (but not family  
history, menarche age)
Postsurgical included 18/18  
postmenopausal; median eMR 0.6
Postmenopausal
Meilahn et al33 UK Prospective, nested  
case-control
Spot urine .50
59 (6.2)
42/139 15/47
16/46
13/46
,1.39
1.39–,2.09
$2.09
1
0.99 (0.48–2.08)
0.75 (0.35–1.62)
NA Age matching; Parity, others not exactly 
specified
Median follow-up 9.5 years;  
median eMR 1.7
Ursin et al39 USA Population-based  
case-control
Spot urine 50–70 66/76 29/26
11/25
26/25
#1.16
1.17–1.73
.1.73
1
0.34 (0.12–0.98)
1.13 (0.46–2.78)
0.96 Age, family history, SeS, education,  
menarche age, parity, weight
Low stage tumors 3–7 years  
after diagnosis; gmean eMR 1.76  
(95% CI : 1.60–1.93)
Muti et al36 Italy Prospective, nested  
case-control
12-h urine 43–70 71/274 12/54
16/55
17/54
12/57
14/54
,1.77
1.77–2.26
2.26–2.80
2.80–3.66
.3.66
1
1.42 (0.60–3.33)
1.41 (0.60–3.33)
1.02 (0.41–2.53)
1.31 (0.53–3.18)
NA Age, BMI, waist-to-hip,  
reproductive variables
Mean follow-up 5.5 years;  
median eMR 2.6
Wellejus et al41 Denmark Prospective, nested  
case-control
Spot urine 50–64 197/197 197/197 log-2-transformed,  
OR for doubling  
of eMR
0.94 (0.71–1.43) NS Age matching only; education,  
parity/first birth age, BMI,  
alcohol, past HT prior tested
Median follow-up 2.4 years  
(P5–P95 0.2–4.9 years); median  
eMR 1.6, P5–P95 0.6–3.5
Kabat et al43 USA Population-based  
case-control
Spot urine ,50–.60 164 (88 is)/197 70/64
62/52
65/48
#1.4
1.5–2.2
$2.3
1
0.97 (0.57–1.64)
0.78 (0.46–1.33)
0.37 Age, first birth age, family  
history, BMI, education, alcohol  
use and medication (48 h prior  
to urine collection)
In situ Ca separately; mean  
eMR (SD) 2.0 (1.0)
Cauley et al40 USA Prospective  
case-cohort
Serum 70 (5)
.65
272/291 69/70
97/72
64/75
72/74
#0.576
0.577–0.749
0.750–0.923
.0.923
1
0.98 (0.62–1.57)
0.89 (0.55–1.42)
1.17 (0.73–1.87)
NA Age, BMI; Family history,  
past HT, education prior tested
Mean follow-up 8.7 years,  
39 in situ Ca included; gmean  
eMR 0.73 (95% CI 0.70–0.76)
eliassen42 USA Prospective, nested  
case-control
Plasma 61.5 (4.7)
43–69
340/677 74/169
89/168
87/170
90/168
,0.28
0.28–,0.37
0.37–,0.48
$0.48
1
1.33 (0.89–1.99)
1.24 (0.83–1.85)
1.30 (0.87–1.95)
0.35 Age matching; BMI at age 18,  
family history, menarche age,  
parity/age at first birth, menopause  
age, duration of past HT use
Follow-up 10–11 years, 63  
in situ Ca included; median  
eMR 0.37
Notes: aFowke et al matched for menopausal status (presurgical: 59 premenopausal and 19 postmenopausal pairs, and postsurgical: 14 pre- and 18 postmenopausal pairs), 
thus estimates refer to both pre- and postmenopausal women.
Abbreviations: BMI, body mass index; Ca, carcinoma; CI, confidence interval; EMR, estrogen metabolite ratio; gmean, geometric mean; HT, hormone therapy; is, in situ; 
NA, not available; NS, not significant; P5–P95, 5th percentile to 95th percentile; SD, standard deviation; SE, standard error; SES, socioeconomic status.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Authors Country Design Medium Age (range and/or  
mean (SD))
Cases/controls  
(total)
Cases/controls 
(in models)
EMR  
(2OHE1/16αOHE1)
Adjusted OR  
(95% CI)
Ptrend Adjustment Notes (median, mean  
or gmean in controls)
Premenopausal
Meilahn et al33 UK Prospective nested  
case-control
Spot urine .34 (40.5 (4.2)) 60/184 21/62
22/61
17/61
,1.72
1.72–,2.44
$2.44
1
0.99 (0.48–2.08)
0.75 (0.35–1.62)
NA Age + menstrual phase  
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not exactly specified
Median follow-up 9.5 years,  
median eMR 2.1
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14/51
11/52
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1.8–2.3
2.3–2.72
2.72–3.29
$3.29
1
0.76 (0.34–1.69)
0.60 (0.25–1.44)
0.62 (0.27–1.45)
0.55 (0.23–1.32)
NA Age + menstrual phase  
matching, BMI,  
waist-to-hip, reproductive  
variables
Mean follow-up 5.5 years,  
median eMR 2.5
Kabat et al43 USA Population-based  
case-control
Spot urine ,50–.60 105 (70 is)/129 44/46
35/42
26/41
#1.4
1.5–2.2
$2.3
1
0.63 (0.33–1.23)
0.50 (0.25–1.01)
0.05 Age matching, parity/first  
birth age, family history,  
BMI, education, medication  
(48 h prior urine collection)
In situ Ca separately; smoking,  
alcohol, diet prior tested; mean  
eMR (SD) 1.9 (1.0)
Arslan et al38 USA Prospective, nested  
case-control 
Serum 35–65
44.3 (4.8)
377/377 Not given for 
quartiles
,0.45
0.453–0.635
0.636–0.936
.0.936
1
0.83 (0.53–1.31)
1.04 (0.65–1.65)
1.13 (0.68–1.87)
0.51 Age + menstrual phase matching; family 
history, ever smoking, BMI, menarche  
age, parity/first birth age
12–18 years of follow-up, mean  
eMR (SD) 0.76 (0.49)
Mixed menopausal
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China Population-based  
case-control
Spot urine 25–65 78/78 presurgical 30/20
25/27
23/31
#0.69
0.70–1.22
$1.22
1
0.5 (0.2–1.3)
0.5 (0.2–1.3)
0.17 Matched for age and menopause; family 
history, physical activity, BMI, age at  
menarche, parity/first birth age,  
fibroadenoma history
Separate models for presurgical and   
postsurgical; presurgical included  
19/19 postmenopausal; median  
eMR 1.0
Fowke et al44  
(postsurgical)a
China Population-based  
case-control
Spot urine 25–65 32/32 postsurgical 5/14
10/11
17/7
#0.69
0.70–1.22
$1.22
1
3.1 (0.4–23.6)
8.1 (1.2–54.6)
0.02 Matched for age and menopause; family 
history, physical activity, BMI, age at  
menarche, parity/first birth age,  
fibroadenoma history (but not family  
history, menarche age)
Postsurgical included 18/18  
postmenopausal; median eMR 0.6
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59 (6.2)
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16/46
13/46
,1.39
1.39–,2.09
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NA Age matching; Parity, others not exactly 
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menarche age, parity, weight
Low stage tumors 3–7 years  
after diagnosis; gmean eMR 1.76  
(95% CI : 1.60–1.93)
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case-control
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2.80–3.66
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1
1.42 (0.60–3.33)
1.41 (0.60–3.33)
1.02 (0.41–2.53)
1.31 (0.53–3.18)
NA Age, BMI, waist-to-hip,  
reproductive variables
Mean follow-up 5.5 years;  
median eMR 2.6
Wellejus et al41 Denmark Prospective, nested  
case-control
Spot urine 50–64 197/197 197/197 log-2-transformed,  
OR for doubling  
of eMR
0.94 (0.71–1.43) NS Age matching only; education,  
parity/first birth age, BMI,  
alcohol, past HT prior tested
Median follow-up 2.4 years  
(P5–P95 0.2–4.9 years); median  
eMR 1.6, P5–P95 0.6–3.5
Kabat et al43 USA Population-based  
case-control
Spot urine ,50–.60 164 (88 is)/197 70/64
62/52
65/48
#1.4
1.5–2.2
$2.3
1
0.97 (0.57–1.64)
0.78 (0.46–1.33)
0.37 Age, first birth age, family  
history, BMI, education, alcohol  
use and medication (48 h prior  
to urine collection)
In situ Ca separately; mean  
eMR (SD) 2.0 (1.0)
Cauley et al40 USA Prospective  
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Serum 70 (5)
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272/291 69/70
97/72
64/75
72/74
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0.98 (0.62–1.57)
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NA Age, BMI; Family history,  
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Mean follow-up 8.7 years,  
39 in situ Ca included; gmean  
eMR 0.73 (95% CI 0.70–0.76)
eliassen42 USA Prospective, nested  
case-control
Plasma 61.5 (4.7)
43–69
340/677 74/169
89/168
87/170
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,0.28
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1.30 (0.87–1.95)
0.35 Age matching; BMI at age 18,  
family history, menarche age,  
parity/age at first birth, menopause  
age, duration of past HT use
Follow-up 10–11 years, 63  
in situ Ca included; median  
eMR 0.37
Notes: aFowke et al matched for menopausal status (presurgical: 59 premenopausal and 19 postmenopausal pairs, and postsurgical: 14 pre- and 18 postmenopausal pairs), 
thus estimates refer to both pre- and postmenopausal women.
Abbreviations: BMI, body mass index; Ca, carcinoma; CI, confidence interval; EMR, estrogen metabolite ratio; gmean, geometric mean; HT, hormone therapy; is, in situ; 
NA, not available; NS, not significant; P5–P95, 5th percentile to 95th percentile; SD, standard deviation; SE, standard error; SES, socioeconomic status.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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All studies but one41 used percentile distributions of the 
EMR among controls to assess the association with breast 
cancer risk by comparing the highest with the   lowest group 
(tertiles, quartiles, or quintiles) with conditional or uncondi-
tional logistic regression or Cox’s40 regression analysis. Welle-
jus et al41 applied log-2-transformed EMR values that reflect 
a doubling of concentration per unit change.   Adjustment for 
potentially confounding factors differed slightly between 
studies. Characteristics that were included in most models 
were age, body mass index (BMI) or   waist-to-hip ratio, and 
reproductive variables known to be risk factors for breast 
cancer. Wellejus et al41 did not adjust their analysis apart 
from matching for exact age, and Cauley et al40 adjusted 
their analysis only for age and BMI. Of the four studies 
that included both pre- and postmenopausal women, three 
analyzed pre- and postmenopausal women separately.33,36,43 
The Shanghai study reported combined estimates based on 
analyses stratified by menopausal status and time of urine 
collection relative to surgery/treatment status.44
Main study results (risk estimates, 95% CI) are 
  presented by specimen and menopausal status in Table 1 
and Figure 1.
Urinary EMR
Premenopausal breast cancer
In the UK study (60 cases), the EMR was associated with 
a nonsignificant 25% risk reduction (first vs third tertile: 
OR = 0.75, 95% CI = 0.35–1.62).33 The Italian study36 
(67 cases) reported nonsignificantly decreased ORs for 
the second to fifth quintile (ORs: Q2–Q5 = 0.76–0.55). 
A 50% risk reduction (95% CI: 0.25–1.01) for the highest 
tertile of the EMR was found in the retrospective study by 
0.55
0.5
0.71
1.13
1.31
0.5
8.1
1.13
1.17
0.75
0.94
0.78
1.3
0.1
Meilhan33 60/184
Muti36 67/264
Kabat43 105/129
Meilhan33 42/139
Ursin39 66/76
Muti36 71/274
Kabat43 164/197
Wellejus41 197/197* 
Fowke44 pre-OP 78/78
Fowke44 post-OP 32/32
Arslan38 377/377
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Eliassen42 340/677
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Figure 1 OR/RR for highest versus lowest quantile of eMR in studies on pre- and postmenopausal breast cancer.
Note: Wellejus used log-2-transformed eMR, representing a doubling of eMR per unit increase.
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Kabat et al.43 Analysis repeated for cases prior to and after 
chemotherapy showed no substantial differences in risk esti-
mates. Fowke et al44 reported results for 78 presurgical (the 
majority being premenopausal) and 32 postsurgical pairs (14 
pairs being premenopausal). For presurgical pairs, the tertiles 
of the EMR were nonsignificantly associated with a 50% 
risk reduction, whereas a significantly positive association 
was present postsurgically (OR for third vs first tertile: 8.1, 
95% CI: 1.2–54.6). Only Kabat et al43 observed an inverse 
  dose–response relationship over tertiles of EMR (Ptrend = 0.05), 
whereas other studies found no trends38,44 or did not provide 
a trend test.33,36
Postmenopausal breast cancer
Meilahn et al33 (42 cases) and Kabat et al43 (164 cases) 
reported nonstatistically significant inverse associations 
for the highest versus lowest tertile of the EMR   (respective 
ORs 0.75 and 0.78), whereas Muti et al36 (71 cases) 
and Ursin et al39 (66 cases) observed nonsignificant risk 
  elevations. Wellejus et al41 found no significant relationship 
among 197 case-control pairs for a doubling of EMR per 
increment (OR: 0.94, 95% CI: 0.71–1.43).
In summary, none of the urinary studies reported a 
  statistically significant inverse association between EMR 
and breast cancer risk, although the premenopausal study by 
Kabat et al43 showed an upper confidence limit close to 1.
Serum/plasma EMR
Premenopausal breast cancer
Arslan et al38 found no association between the serum EMR 
and premenopausal breast cancer risk among 377   case-control 
pairs, the OR for the top versus bottom quartile being 1.13 
(95% CI: 0.68–1.87). Repeated analyses according to 
  menstrual cycle phase (follicular pairs and luteal pairs) or 
after excluding cases diagnosed within 5 or 10 years after 
enrollment did not yield different results.
Postmenopausal breast cancer
Eliassen et al42 and Cauley et al40 included in situ cases in 
their analyses of 340 and 272 cases, respectively. Both studies 
found nonsignificant risk elevations for the highest compared 
with the lowest quartile of circulating EMR levels. Thus, 
the serum/plasma EMR was not significantly associated to 
pre- or postmenopausal breast cancer.
Heterogeneity testing
The test for heterogeneity across the combined pre- and 
  postmenopausal urinary studies (Pheterogeneity = 0.86) and the 
test for circulating EMR studies (Pheterogeneity = 0.86) were 
  negative. Additionally, the test for heterogeneity across all 
nine urinary and circulating EMR studies revealed no signifi-
cant inconsistency between studies (Pheterogeneity = 0.61).
Breast cancer subtypes: receptor status 
and in situ cancer
Kabat et al found the urinary EMR to be statistically, 
  significantly, and inversely related to ER-positive 
  premenopausal tumors (third vs first tertile OR: 0.32, 
95% CI: 0.12–0.84) and nonsignificantly related to 
  ER-negative tumors in postmenopausal women (OR: 0.38, 
95% CI: 0.15–1.01).43 A nonsignificant inverse association in 
ER-negative cases (OR for doubling of urinary EMR: 0.78, 
95% CI: 0.42–1.48) was also reported by Wellejus et al.41 
In contrast, serum/plasma levels of EMR were increased 
in ER-negative postmenopausal cases (OR: 3.7, 95% 
CI: 1.24–11.09, Ptrend = 0.004, Pheterogeneity = 0.005) in one 
study42 and in ER-positive premenopausal cases in the 
other study (OR: 2.15, 95% CI: 0.88–5.27).38 Apart from 
Eliassen et al42 none of the studies tested for heterogeneity 
by ER status.
Kabat et al43 separately investigated 70 premenopausal 
and 88 postmenopausal cases with carcinoma in situ of the 
breast. No association of EMR was observed in both groups. 
Likewise, from their overall negative results, Eliassen et al42 
reported no differential relationship for postmenopausal in 
situ breast cancer.
Discussion
Summary of main results
Overall, nine studies that fulfilled our inclusion criteria 
investigated the association between the EMR of 2- to 
16α-hydroxyestrone and breast cancer risk, six of which 
examined urinary and three circulating EMR. Studies on 
urinary EMR found ORs between 0.50 and 0.75 (except 
for the postsurgical OR in Fowke et al)44 in premenopausal 
women and between 0.71 and 1.31 in postmenopausal 
women, comparing the highest with the lowest quantiles 
or, in one study, a doubling of EMR. Although none of the 
studies reached statistical significance, the premenopausal 
arm of the retrospective study by Kabat et al was borderline 
significant, suggesting that an inverse association of urinary 
EMR might be confined to premenopausal breast cancer. 
However, there was no differential effect in all urinary 
studies combined (Pheterogeneity = 0.86), which contradicts a 
hypothesized modification by menopausal status. Similarly, 
the circulating EMR was not associated with breast cancer International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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risk in pre- or postmenopausal women (ORs ranging from 
1.13 to 1.30, Pheterogeneity = 0.86). There was also no significant 
heterogeneity across all combined urinary and serum/plasma 
studies (Pheterogeneity = 0.61).
Receptor status and in situ carcinomas
Limited data on ER status with contradictory results do 
not allow a firm conclusion regarding heterogeneity in the 
  relationship between EMR and breast cancer risk by ER 
  status. The two studies, which investigated in situ carcinomas 
separately, did not find the EMR to be inversely associated 
with risk of in situ breast cancer.
Quality of evidence
Completeness of data
Exclusion of two earlier small studies,16,17 which found strong 
inverse associations for EMR, may have led to certain bias 
toward null results, but these studies were not included due 
to flaws in design or reporting. A funnel plot (Figure 2), 
including these studies, suggested that there might have been 
publication bias in this early phase. Another larger excluded 
study that assessed only single estrogen metabolites in serum 
of postmenopausal hormone therapy nonusers did not report 
statistically significant associations with breast cancer risk.47 
Though not necessarily, it is likely that the EMR was also 
not associated with breast cancer in this study.
Study size and power
The earliest publications that reported an inverse association 
between EMR and breast cancer risk were based on small 
numbers and thus have a tendency to overestimate the 
effect. Many of the subsequently published studies also had 
relatively small study sizes33,36,39,44 and consequently limited 
statistical power to detect a significant risk reduction of 
about 30% (likely effect magnitude based on the first cohort 
studies).33,36 If tertiles of exposure are considered, at least 200 
case-control pairs are needed to identify a 50% risk reduction 
and 400 pairs to detect a relative risk of 0.7 with 80% power 
at an alpha of 0.05.52
Study design
The studies were heterogeneously designed, including 
both prospective and retrospective studies, using urinary or 
circulating EMR measurements for exposure assessment, 
including diverse populations, and many lacking statistical 
power. These variations may partly explain the differences 
in risk estimates for EMR.
The  EMR  may  be  influenced  by  disease  status 
  (tumor-driven activity), stage, and treatment.18,43,44,53 Thus, 
the hypothesized association between the EMR and breast 
cancer might be subject to reverse causation in retrospec-
tive   case-control studies. Fowke et al44 found a decreased 
EMR risk in presurgical cases and an increased EMR risk 
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in postsurgical cases. If pre- and postsurgery subgroups 
were combined, this would have resulted in a crude OR for 
the EMR of 1.02 (95% CI: 0.72–1.25). Hence, an existing 
inverse association may be masked by a potential influ-
ence of treatment on EMR. No study actually assessed the 
intraindividual variability in EMR before and after a breast 
cancer diagnosis. Therefore, prospective studies of EMR 
will be required to elucidate a potential association of EMR 
with breast cancer.
Adjustment for confounders in the individual studies
Only studies that excluded current users of exogenous 
  hormones were included in this review, as oral   contraceptives 
and menopausal hormone therapy have been shown to 
increase54–57 or decrease EMR.41,47 Many of the known breast 
cancer risk factors, such as reproductive variables (ie,   parity 
and age at first birth) and BMI, which have been found to 
be associated with the EMR,42,58 were controlled in most 
included studies. Menstrual cycle phase in premenopausal 
women, a family history of breast cancer, and a history of 
benign breast disease were not consistently adjusted for. 
Although little evidence indicates that EMR is associated 
with a family history59 or benign breast disease, circulat-
ing EMR has been shown to increase during the menstrual 
cycle.60 Urinary estrogen metabolite levels vary strongly by 
ethnicity, showing lowest mean values in healthy African 
Americans followed by Asians and Caucasians.32,45,61–64 
Although ethnic variations in plasma EMR were less 
pronounced,55 uncontrolled confounding could have masked, 
diluted, or even pretended a potential EMR effect in studies 
not adjusted for ethnicity depending on the combination 
of case-control pairs (even if percentages [other than for 
  Caucasians] were as low as 12%–16%).38,43 However, in some 
studies, adjusted risk estimates did not differ substantially 
from crude estimates, and EMR varied only slightly across 
categories of covariates.33,36,40,41 Therefore, the risk estimates 
in these studies were considered as appropriate.
Possible modifiers of the association  
between eMR and breast cancer
Menopausal status did not strongly affect EMR in most 
studies, which is compatible with the observed overlapping 
distributions of EMR in pre- and postmenopausal women.32 
Genetic makeup and differential activity of metabolizing 
hydroxylases and other enzymes (eg, COMT) have been 
estimated to explain most of the variation in EMR.65 In 
addition, estrogen hydroxylation pathways, particularly 
2-hydroxylation, are believed to be modifiable through 
diet, physical activity, smoking, alcohol consumption, and 
  caffeine intake. Clinical trials and observational studies 
generated inconsistent results regarding a potential influence 
of diet (eg, soy products, fat/fiber, and Brassica vegetables) 
and physical activity habits on EMR. Studies in the present 
review do not support that EMR may be associated with 
breast cancer risk in specific subgroups.
Reliability of measurements
Reliability of a single urinary EMR measurement in 
  premenopausal women was rated sufficient in studies on 
  variation in intraindividual EMR during the menstrual cycle.31,66 
Intraclass correlation coefficients between two urinary EMR 
measurements were 0.71 over a 1-year period67 and 0.6730 over 
a 6-month period, and between two plasma EMR measurements 
were 0.73 over a 3-year period.42 All included studies, except 
for the study by Meilahn et al,33 used a refined version of the 
ESTRAMET enzyme immunoassay to determine the EMR of 
2OHE1/16αOHE1 validated against a gas chromatography/
mass spectrometry (MS) method. This assay could more 
sensitively detect estrogen metabolites in the lower postmeno-
pausal range than the first version.68 However, a recent study 
rated reliability of urinary estrogen metabolite determination 
of postmenopausal women by this enzyme immunoassay 
problematic compared with a new technique involving liquid 
chromatography (LC)–MS/MS.69 Studies of postmenopausal 
women reported higher between-assay coefficients of variation 
than those of premenopausal women. Serum and plasma mea-
surements are even more susceptible to errors because of the 
lower metabolite concentrations. Further, variation within and 
between studies may have resulted from differing specimens’ 
sampling patterns, storage length, and time between sampling 
and diagnoses in prospective studies.
Findings that oppose  
the postulated hypothesis
Well-established risk factors for breast cancer that are 
  considered to be related to estrogen exposure, eg, family 
history, age at menarche, and benign breast disease,38 were 
not substantially or even inversely associated to the EMR, ie, 
a lower EMR with higher parity,38 lower age at first birth,58 
and high breast density,70 respectively. Furthermore, ethnic 
differences in the EMR do not correspond to breast cancer 
incidence patterns in Asians and Caucasians. Differences in 
breast cancer risk between Asians and African Americans 
were found to be better explained by urinary estradiol, E1, 
and estriol than by EMR in a cross-sectional study of healthy, 
nonestrogen-using women.71International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Recommendations for future studies
Interrelationship of urinary, circulating,  
and tissue eMR
Urinary and circulating estrogen metabolites may not be 
representative of target tissue concentrations of unconjugated 
metabolites. A recent study of nine patients concluded that 
the urinary EMR is a good approximation for breast tissue 
EMR.72 This result needs to be confirmed in women without 
breast cancer. Moreover, differences in median EMR of 
serum/plasma and urine samples raise the question of whether 
risk estimates derived from urinary EMR can be compared 
with those based on circulating EMR. A single study in young 
women not using oral contraceptives found fair correlation 
coefficients between urinary and plasma EMR (rs = 0.60 in 
Caucasians).60 Hence, further assessment of intraindividual 
correlations between serum/plasma and urinary EMR both 
in patients and in healthy individuals is warranted.
Association between eMR and subtypes  
of breast cancer
There is now ample evidence of etiologic heterogeneity 
for breast cancer subtypes.73 Therefore, the potential for a 
differential role of EMR and other estrogen metabolites in 
subtypes of breast tumors (eg, by ER status, high grade) 
should be investigated in larger prospective studies with 
sufficient power.
Measurement of the catecholestrogens 
4OHe1/4OHe2
The 4-hydroxylation of estrogens leading to the   potentially 
carcinogenic catecholestrogens 4OHE1/4OHE2 is   positively 
correlated to 2-hydroxylation and might be negatively corre-
lated to 16αOHE1, depending on the extent of   cross-reactivity 
of the CYP1A1/A2 pathway.74 Studies in breast tissue have 
gained some insight into the relative and absolute amounts 
of estrogens and their metabolites. Although a higher EMR 
has been found in normal breast tissues,75   supporting the 
  hypothesized role of 16αOHE1, the most abundant   metabolite 
in cancer tissues was 4OHE2. A study by Rogan et al76 
detected significantly higher tissue levels of 4OHE1 but not 
16OHE1 in 28 cases compared with 46 controls. Additionally, 
higher concentrations of quinone conjugates derivatives were 
found in cancer   tissues and interpreted as higher potential 
for quinones to react with DNA. Finally, in a small study, 
  Gaikwad et al49 focused on   depurinating DNA adduct forma-
tion in relation to   catecholestrogen   concentration, expressed as 
a ratio. Higher ratio levels, particularly for 4OHE   conjugates 
indicating a relatively higher DNA adduct formation, were 
seen in cases and in a high-risk group than in controls 
  (confirmed in an extended group).77 These preliminary find-
ings may advise the future direction of research to include the 
  detection of 4OHE1 and 4OHE2 in epidemiological studies 
of 2OHE1/16αOHE1 EMR.
Conclusion
All of nine properly designed epidemiological studies 
(six prospective case-control studies and three retrospective 
studies) failed to show a significant relationship between 
urinary or circulating EMR (2OHE1/16αOHE1) and breast 
cancer risk. Although premenopausal studies on urinary 
EMR have suggested a potentially weak inverse   relationship, 
  associations were not significantly different compared with 
postmenopausal or overall combined studies. Thus, at   present, 
there is no evidence that the EMR can predict breast cancer 
risk. Larger prospective studies are needed to definitely assess 
a potential association of EMR with risk of breast cancer and 
risk by subtype (eg, by ER), adjusting for age, menstrual 
cycle phase, and ethnicity and menopausal status in cases 
of mixed study populations. A deeper   knowledge of inter-
relationships between urinary, circulating, and tissue levels 
of estrogen metabolites would help to integrate studies with 
respect to target tissue values. The measurement of further 
estrogen metabolites by new LC–MS/MS methods to provide 
a more complete profile, particularly of 4-hydroxylated and 
methylated estrogens, may lead to more promising markers 
for breast cancer.
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